Do sildenafil 100 mg, vitamin D3 (cholecalciferol) and vitamin K2 (menaquinone) interact with N‑acetylcysteine or milk‑thistle (silymarin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Clinically Significant Interactions Between These Supplements

Based on FDA drug labeling and current pharmacokinetic evidence, sildenafil 100 mg, vitamin D3, and vitamin K2 do not have clinically significant interactions with N-acetylcysteine (NAC) or milk thistle (silymarin) at standard supplemental doses.

Sildenafil and NAC

NAC does not interact with sildenafil through metabolic pathways. The FDA label for sildenafil identifies CYP3A4 (major) and CYP2C9 (minor) as the primary metabolic enzymes 1. NAC is not an inhibitor or inducer of these pathways.

  • Research actually suggests NAC may enhance sildenafil's beneficial effects in certain conditions (pulmonary thromboembolism model), working synergistically rather than antagonistically 2
  • No documented adverse interactions exist in clinical literature
  • NAC's antioxidant mechanism operates independently of sildenafil's phosphodiesterase-5 inhibition

Sildenafil and Milk Thistle

Milk thistle (silymarin) poses minimal interaction risk with sildenafil despite theoretical concerns. While in vitro studies show silymarin can inhibit CYP3A4 and various drug transporters, these effects do not translate to clinically relevant interactions 3, 4.

Key evidence:

  • Systematic reviews confirm that silymarin's inhibitory concentrations are "too high to be relevant under real biological conditions" 4
  • Most human studies show no silymarin-drug interactions despite the suggested enzyme interference 4
  • The 2016 ESC/ERS guidelines note that St. John's wort (a potent CYP3A4 inducer) may lower sildenafil levels 5, but milk thistle is not mentioned as a concern—a significant omission given the comprehensive drug interaction section
  • Silymarin's poor oral bioavailability (only 1-5% reaches systemic circulation) further limits interaction potential 4

Vitamin D3 and K2

Neither vitamin D3 nor K2 interacts with sildenafil, NAC, or milk thistle:

  • Vitamin D3 is not metabolized by CYP3A4 or CYP2C9
  • Vitamin K2 does not affect cytochrome P450 enzymes
  • No documented interactions exist between these fat-soluble vitamins and the other supplements in question
  • Recent research combining cholecalciferol with silymarin for benign prostatic hyperplasia showed no safety concerns 6

Important Caveats

The only documented sildenafil interactions requiring clinical attention are:

  • Nitrates (absolute contraindication—can cause life-threatening hypotension) 7, 8, 1
  • Potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir)—increase sildenafil levels 30% or more 5, 1
  • Antihypertensive medications—additive blood pressure lowering 5

Practical recommendation: You can safely take all five substances together. Monitor for sildenafil's common side effects (headache, flushing, dyspepsia) which are unrelated to these supplements 8, 1. If taking sildenafil for erectile dysfunction, ensure proper timing (1 hour before activity) and sexual stimulation 7.

References

Research

Metabolism, Transport and Drug-Drug Interactions of Silymarin.

Molecules (Basel, Switzerland), 2019

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.